Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Beam Therapeutics IncBEAM-13.455.522.44-8.54-18.29%-22.65%56.94$24.72$212.6929,623$23.44

Detail of Beam Therapeutics Inc

 
CEO
Mr. John M. Evans M.B.A.
Employees
472
Industry
Biotechnology
Sector
Healthcare
Market cap
$2B

Company details

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Revenue
Revenue (Rev)
$349.64M
Beam Therapeutics Inc
BEAM • XNGS • US
$23.44
-1.31 (-5.29%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$1.74
Margin profit
-41.07%
52 week low
$21.219999
52 week high
$45.099998
50-day simple moving average
$24.66
200-day simple moving average
$24.72
Percent held by insiders
1.42%
Percent held by institutions
93.09%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
BEAM -5.29%
eps change
BEAM 0.00%